The Impact of Family History of Colon Cancer on Survival after Diagnosis with Colon Cancer
|
|
- Bennett Henry
- 5 years ago
- Views:
Transcription
1 International Journal of Epidemiology O International Epfdemlotoglcal Association 1995 Vol. 24, No. 5 Printed In Great Britain The Impact of Family History of Colon Cancer on Survival after Diagnosis with Colon Cancer MARTHA L SLATTERY AND RICHARD A KERBER Slattery M L (Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT 84132, USA) and Kerber R A. The impact of family history of colon cancer on survival after diagnosis with colon cancer. International Journal of Epidemiology 1995; 24: Background. The impact of family history of colon cancer on survival after diagnosis with colon cancer is generally unknown. It is possible that family history Is indicative of a genetically inherited form of disease which may alter survival. Methods. The Utah Population Database was used to evaluate survival after diagnosis with colon cancer among 2236 first primary colon cancer cases. This database includes detailed information about family history and is linked to the Utah Cancer Registry to obtain tumour information. Results. Stage at diagnosis was the primary factor associated with death from all causes and from colon cancer. An older age at diagnosis, being female, and having a tumour in the ascending segment of the colon also were associated with poorer survival, although after adjusting for stage at diagnosis these associations disappeared. Having a family history of colon cancer had little impact on survival patterns although there were suggestions that men who were diagnosed.at age <55 were more likely to die from all causes as well as colon cancer If they had a sibling with colon cancer (hazard rate ratio [HRR] 2.50, 95% confidence interval [Cl] : ) relative to men >55 without a sibling with colon cancer. Conclusions. From these data it appears that the major factor which Increases survival Is being diagnosed at an early stage of disease. These data also suggest that younger men who have a sibling with colon cancer may have a different form of colon cancer which increases their risk of dying. Keywords, colonic neoplasia, family history of cancer, survival Factors which influence survival after diagnosis with cancer are not well understood. While most research has focused on treatment methods which may influence survival, little is known about factors which are intrinsic to the individual, including family history of cancer and lifestyle, and their impact on survival. Family history has been evaluated as a factor which could influence survival with breast cancer.'" 5 However little is known about the impact of family history of colon cancer on survival after diagnosis with colon cancer. One study 5 showed that those with hereditary colon cancer had slightly better survival than those without a family history of colon cancer and that those diagnosed at a younger age had better survival. 5 ' 6 Likewise, individuals whose tumours have various genetic alterations have been shown to have different survival patterns. 7 Thus, it is possible that genetic factors which are associated with and expressed as a positive family history of the disease may influence survival once diagnosed. Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT 84132, USA. 888 In this study we use the Utah Population Database (UPDB), a linked database which consists of genealogy data and Utah Cancer Registry (UCR) data to examine survival patterns of people diagnosed with colon cancer. With this database we have access to detailed family history information which in some instances goes back seven generations. METHODS In this study we include 2236 cases (1114 women and 1122 men) of first primary colon cancer recorded in the Utah Cancer Registry (UCR) with a date of diagnosis after 1965 and who link to the UPDB genealogy database. The UCR is a population-based registry of cancers occurring in Utah. In 1966, the cancer registry began collecting tumour information throughout the state; in 1972 it became part of the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) Program. Data from the UCR have been linked to the genealogy database, a computerized database that contains family information on over one million
2 COLON CANCER SURVIVAL 889 descendants of the Utah pioneers. 8 ' 9 Records from the UCR were linked to the UPDB database via probabilistic record-linking software developed by RAK. Last, first, and middle names, parts of names, dates of birth and death, and place of birth were used to link records. Records with ambiguous linking scores were hand checked. For married women, marriage records from the UPDB genealogy were used to generate married names, and second and third names given in cancer registry record were evaluated as possible maiden names. The percentage of colon cancer records linked to the genealogy database was 43.1% for men and 43.0% for women. In general, the proportion of cancer records linked to the genealogy decreased with increasing birth year, particularly for women. No differences in stage of disease at diagnosis were observed between linked and unlinked cases. Data obtained from the UCR included the age at diagnosis, the total number of months survived, the date of last observation, vital status, site of the tumour at diagnosis, and stage of the tumour at diagnosis. 10 The SEER summary stage codes were used to evaluate the impact of disease stage at diagnosis on survival. These codes take into account the tumour size and extent, node involvement, and metastasis. Tumours at a local stage are those which invade the submucosa or muscularis propria, have no lymph node involvement, and no metastasis. Tumours defined as regional invade through the muscularis propria into the subserosa or into non-peritonealized pericolic or perirectal tissues, or perforate the visceral peritoneum or other organs or structures such as small intestine, abdominal fat wall or enterperitenoneum; they have no lymph node involvement or metastasis. Distant tumours are those which invade other more distant organs such as the gallbladder, diaphragm, or adrenal glands, have lymph node involvement and distant metastasis. Tumour registry data were used to estimate length of survival. Genealogy data were used to develop family history profiles. Together these data were used to determine familial risk estimates of colon cancer and their impact on survival. Family History Definitions Family history was defined several ways. The most comprehensive family history measure we used was the familial standardized incidence ratio (FSIR). This measure takes into account the variability in family size and person-time at risk among the families of subjects. It weights the observed familial cancer rates by kinship to the subject."' 12 We also have defined family history by kinship order, including first, second, third, and fourth and greater kinship ranking. Firstdegree relatives include mothers, fathers, children, brothers and sisters, second-degree relatives include grandparents and aunts and uncles, third-degree relatives include first cousins and great grandparents, fourth-degree relatives include second cousins, greatgreat grandparents, great aunts and uncles, and more distant relatives. We further examine type of firstdegree relative with cancer since much of the reported literature has focused on the first-degree relative. Statistical Analyses Familial risk calculation. Familial risk was calculated as a familial standardized incidence ratio (FSIR). For each subject we did a comprehensive search of all the subject's relatives (ascending, descending, and collateral), and calculated observed and expected cases of colon and other cancers within six age- and sex-specific categories. Both observed and expected cancer counts were weighted by a kinship coefficient which measures the probability that the subject and his or her relative share a random gene through common descent. After all relatives were searched, FSIR was calculated by summing observed and expected cases across age and sex categories, and dividing total observed by total expected." Other statistical methods. The distribution of the population in terms of having a family history of colon cancer was assessed. We also evaluated the sex-specific survival associations and other factors which could be associated with survival, including the age at diagnosis, stage at diagnosis, and the site of the tumour within the colon. Proximal or ascending tumours were defined as tumours in the caecum, ascending, hepatic flexure and transverse segments of the colon; distal or descending tumours included those located in the splenic flexure, descending and sigmoid parts of the colon. The months of observation were calculated from the month of diagnosis until the month of death. Months of observation for people still alive or lost to follow-up were counted from the date of diagnosis until the date of last contact. We calculated median survival times, using the product-limit (Kaplan-Meier) estimate. 13 Median survival times are presented as the time in which 50% of the population had either died from any cause, were censored as alive, or were censored at the date of last contact. Brookmeyer-Crowley 95% confidence intervals (CI) on the median survival times are presented along with Breslow estimates of differences in survival between groups (BMDP). We used Cox proportional hazard techniques to estimate hazard rate ratios (HRR)
3 890 INTERNATIONAL JOURNAL OF EPIDEMIOLOGY and corresponding 95% CI associated with family history. In these analyses we took into account stage at diagnosis and age at diagnosis. We excluded people for whom stage of diagnosis was unknown (N = 201) from the proportional hazards models. We stratified the data by age at diagnosis (S55 and >55). We estimated survival for deaths from all causes and for deaths from colon cancer only. When evaluating deaths from colon cancer only, we censored deaths from other causes. RESULTS Of the 1114 women and 1122 men diagnosed with colon cancer, 72.0% (802) of the women and 71.8% (806) of the men had died. For both women and men, the primary cause of death reported was colon cancer accounting for 458 (57.1%) deaths among women and 402 (49.9%) deaths among men. Other cancers accounted for 9.9% of deaths (n = 79) among women and 11.7% (n = 94) among men. The most frequently occurring other cancer deaths for women were rectal cancer (11 or 1.4% of deaths), other gastrointenstinal cancers (13 or 1.6% of deaths), and unknown primary (18 or 2.2% of deaths). Among men, the most frequently occurring other deaths from cancer were rectal cancer (11 or 1.4% of deaths), other gastrointenstinal cancers (18 or 2.2% of deaths), unknown primary (17 or 2.1% of deaths), cancers of the gallbladder, lung, or prostate (8 each or 1% of deaths each). The primary factors associated with crude survival include age, stage of disease at diagnosis, and tumour site within the colon (Table 1). The median survival was less among older men and women, those diagnosed at a more advanced stage of disease, and those whose tumour was located in the ascending segment of the colon. Among men, those with a higher familial risk score had better crude survival than those with less of a family history. We also characterized survival by short-term survival (=S24 months) and by longer-term survival (Table 2). We observed that among women, those >65 years at the time of diagnosis, those diagnosed at a more distant stage of disease, and those with tumours in the ascending segment of the colon were more likely to die within 24 months of diagnosis. Evaluation of a family history of colon cancer did not show any associations with survival. The most pronounced indicator of risk of death from all causes and from colon cancer was diagnosis at a late stage of disease. The HRR of dying from any cause was approximately 8 and for dying from colon cancer was 13 when diagnosed at a distant stage of disease relative to diagnosis at a local stage of disease. After adjustment for stage of disease and age at diagnosis, there were no differences in risk of dying for men versus women or ascending versus descending tumours. Family history of colon cancer did not appear to alter one's risk of dying from any cause or from colon cancer in either men or women when examining all ages combined (Table 3). We further evaluated the age at which diagnosis occurred and risk of dying if one had a family history of colon cancer (Table 4). Among women age >55 and men =S55 years, we observed that risk of dying from colon cancer increased if a sibling had colon cancer. Among younger men, a twofold increase in risk of death was observed if their sibling had been diagnosed with colon cancer relative to younger men without a sibling with colon cancer. No alteration in risk was observed if parents had colon cancer. Findings were similar for all-cause mortality as for deaths from colon cancer. We further evaluated the interaction between age at diagnosis, sex, and having a sibling with colon cancer and survival (Table 5). We observed that men diagnosed at age *55 with a sibling with colon cancer had a relative risk of 2.50 of dying of any cause (95% CI : ) compared to men >55 without a sibling with colon cancer. The HRR for younger women with a sibling with colon cancer was 1.10 (95% CI: ). Similar interactions were observed when analysing deaths from colon cancer. Stage at diagnosis was a major factor associated with survival. We therefore examined factors which might be associated with stage at which the tumour is diagnosed (Table 6). We found that more men than women were diagnosed at a local stage and that stage was unknown for more women than men. Among cases >65, the stage was unknown more frequently than for younger people. Tumours in the descending segment of the colon were more frequently diagnosed at an earlier stage. These associations were observed for both men and women. The only indicator of family history associated with stage of diagnosis was having a sibling with colon cancer which was associated with an earlier diagnosis. Overall, the association between stage at diagnosis and having a sibling with colon cancer was of borderline significance (P = 0.08) when tumours at an unknown stage were included and significant (P = 0.04) when those tumours with an unknown stage were excluded. When examining sex-specific associations similar findings were observed. DISCUSSION Lifestyle and family history of cancer could potentially alter survival if environmental and genetic factors
4 COLON CANCER SURVIVAL 891 TABLE 1 Description of study population Median survival time (95% CI)* Dead(N9t>) Censored (N») Dead(N%) Censored (N%) Total Sex (27, 37) 39 (33, 44) Age at diagnosis S >65 (Breslow) Stage at diagnosis' 1 Local Regional Distant / -value (Breslow) Site of tumour in the colon 0 Ascending Descending (Breslow) (Breslow) (Breslow) (Breslow) < -1.9 (Breslow) 32 (4.0) 167 (20.8) 603 (75.2) 180 (26.0) 273 (39.5) 238 (34.4) 364 (52.0) 336 (48.0) 788 (98.2) 14(1.7) 746 (93.0) 56 (7.0) 70 (8.7) 43 (5.4) 105(13.1) 584 (72.8) 479 (59.7) 150(18.7) 109(13.6) 64 (8.0) 33 (10.6) 98(31.4) 181 (58.0) 154(51.3) 138(46.0) 8 (2.7) 115(38.7) 182(61.3) 303(97.1) 9 (2.9) 291 (93.3) 21 (6.7) 29 (9.3) 18(5.8) 45(14.4) 220 (70 5) 176(56.4) 63 (20.2) 43 (13.8) 30 (9.6) 37 (4.6) 197 (24.4) 572(7) 189 (25.6) 326 (44.2) 223 (30.2) 343 (47.4) 381 (52.6) 788 (97.8) 18 (2.2) 745 (92.4) 61 (7.6) 77 (9.6) 47 (5.8) 126(15.6) 556 (69.0) 466 (57.8) 148(18.4) 131 (16.3) 61 (7.6) 32(10.1) 116(36.7) 168 (53.2) 176 (57.5) 120 (39.2) 10(3.3) 120 (40.4) 177 (59.6) 309 (97.8) 7 (2.2) 295 (93.3) 21 (6.6) 27 (8.5) 19 (6.0) 50(15.8) 220 (70.0) 183 (57.9) 63(19.9) 45(14.2) 25 (7.9) 93 (39, -) 53(38,71) 24 (20, 29) 109(89, 131) 50 (40, 58) 6 (5, 7) 29 (22, 34) 49 (38, 66) 32 (26, 37) 38(14,-) (26, 36) 41 (18,57) (19,57) 52(21,87) 24(16,39) 32 (26, 38) (28, 42) 25(18,36) 27(17,50) 42 (24, 59) (25,-) 64 (46, 86) 30 (26, 35) 118(96, 143) 42 (36, 54) 6 (5, 6) 30(21,38) 50(40,61) 38 (32, 44) 59(12,76) (32, 43) 52(27,71) (29,71) 30 (20, 70) 34 (22, 48) 39 (32, 46) (30, 42) 32 (22, 46) 48 (30, 57) 65 (37, 90) (43,-) 58 (46, 71) 27 (24, 30) 113(103, 129) 47 (39, 53) 6 (5, 6) 29 (24, 33) 49 (42, 60) 35(31,38) 55 (20, 76) (31,38) 42 (27, 59) (29, 57) 39 (27, 70) 30 (22, 39) 35(31,38) (29, 57) 39 (27, 70) 30 (22, 39) 35(31,38) 0.29 ' Median survival time in months. 95* confidence interval (Cl) calculated by Brookmeyer-Crowly. If ties in data occur, CI cannot be calculated. b Stage at diagnosis unknown for 78 men and 123 women. c Site of tumour unknown for 101 men and 117 women.
5 892 INTERNATIONAL JOURNAL OF EPIDEMIOLOGY TABLE 2 Characteristics of study population by length of survival in months <24 Months Survival time Months >60 Months Sex / -value (47.9) (42.7) (20.0) (24.6) (32.0) (32.7) Age at diagnosis < >65 Stage at diagnosis* Local Regional Distant Site of tumour in the colon b Ascending Descending < (35.1) (35.3) (50.0) (21.6) (35.8) (87.7) (48.9) (37.7) (45.4) (39.6) (45.6) (41.5) (40.9) (41.7) (50.3) (45.1) (45.2) (49.3) (44.5) (46.7) (20.9) (23.7) (21.9) (26.5) (29.1) (7.7) (23.3) (23.8) (22.3) (25.0) (22.2) (23.9) (24.1) (24.4) (19.0) (22 6) (22.3) (2) (22.3) (21.9) (44.0) (4) (28.1) (51.9) (35.1) (4.6) (27.7) (38.5) (32.3) (35.4) (32.2) (34.6) (30.9) (33.9) (30.7) (32.3) (32.4) (29.7) (33.2) (31.4) "Excludes 201 with unknown stage. b Excludes 218 with unknown site.
6 COLON CANCER SURVIVAL 893 TABLE 3 Hazard rate ratio (HRRf for family history for all causes mortality and from colon cancer by family history All causes Colon cancer All causes Colon cancer < ( ) 1.19 ( ) 0.97 ( ) 0.91 ( ) 1.13 ( ) 0.92 ( ) 1.14 ( ) 1.12 ( ) 0.82 ( ).0 ().83 ( ) ( ).09 ( ) 8 ( ) 1 ( ) 1.10 ( ).0.11 ( ).15 ( ).06 ( ) 0.90 ( ).0.12 ( ) 1.37 (3-1.83).07 ( ) 6 ( ) 0.99 ( ) ' HRR calculated from Cox proportional hazard models and adjusted for age and stage at diagnosis. influence the disease. Using data from the UPDB we evaluated the impact of a family history of colon cancer on survival once diagnosed. We observed that having a sibling with colon cancer had an impact on survival which was influenced by gender and age at diagnosis. who were age = 55 at the time of diagnosis were more likely to die (from any cause or colon cancer) if they had a sibling with colon cancer. We did not observe an increase in risk for having a parent with colon cancer, although there were few people in this database who had a parent with colon cancer. These findings are opposite to those which we observed for breast cancer, where we observed that having a sibling with breast cancer increased survival while having a parent with breast cancer decreased survival. 3 Results from this study suggest that there are different survival patterns within certain subgroups of those who develop colon cancer. Despite the fact that those with a sibling were generally diagnosed at an earlier stage of disease, survival was worse among men = 55 if they had a sibling with colon cancer after controlling for stage at diagnosis. This may indicate a genetically different form of colon cancer which is more severe, or shared environmental factors which may act differently given an inherited genetic predisposition to colon cancer. Differences in risk by age at diagnosis and sex have been observed for colon cancer development. l4tl5 Descriptive data suggest differences in colon cancer 0.89 ( ) 0.98 ( ) 1.22 ( ) 2 ( ) 0.98 ( ) 1.26 ( ) 0.94 ( ) 0.84 ( ) incidence by age and sex and analytical data support these observations. It has been shown in some studies that diet carries less risk among men diagnosed at a younger versus older age while reproductive factors may differ in their relationship to risk of colon cancer by age at diagnosis. 14 " 16 These differences observed in aetiology may contribute to different forms of disease and thus the different survival patterns for young and old men and women which we observed. Although marginally significant, the increased risk of death among younger men with an affected sibling might conceivably be a chance observation. As has been shown by others 6 the major factor affecting survival is stage at diagnosis, with those diagnosed at a more advanced stage being more likely to die. Thus, early detection is probably the major contributor to better survival. Although we do not have data on screening practices of the population, we were able to examine factors which could be associated with stage of the tumour at diagnosis. We observed that men were more likely to be diagnosed at an earlier stage of disease than were women. Likewise, tumours in the descending segment of the colon were more likely to be detected at an early stage than were tumours in the ascending segment of the colon. People with a sibling with colon cancer were more likely to be diagnosed at an earlier stage, while having a parent with colon cancer did not alter the stage at diagnosis. The differential effect on survival of site of the tumour, age at
7 894 INTERNATIONAL JOURNAL OF EPIDEMIOLOGY TABLE 4 Hazard rate ratio (HRR) associated with family history for all causes of mortality and colon cancer mortality by age at diagnosis All causes Colon cancer All causes Colon cancer Age at diagnosis >55 years < -1 9 Age at diagnosis <55 years < ( ) 1.19 ( ) 0.89 ( ) 0.88 ( ) 1.12 ( ) 0.88 ( ) 3 ( ) 1 15 ( ) 0.77 ( ) 5 ( ) 0.94 ( ) 0.87 ( ) 1.66 ( ) 1.46 ( ) 1.89 ( ) 0.56 ( ) 0.74 ( ) 1.29 ( ) 3 ( ) ( ) 1.16 ( ) 0.83 ( ) 1.31 ( ) 1.15 ( ) 6 ( ) _b 1.36 ( ) 0.80 ( ) 0.59 ( ) 1.55 ( ) 1.62 ( ) 0.23 ( ) * HRR calculated from Cox proportional hazard models and adjusted for age and stage at diagnosis. 'Unable to calculate since no one had died who had a sibling with colon cancer. diagnosis, and sex was the result of stage at diagnosis, although these differences could have implications for screening practices. In summary, we observed that having a family history of colon cancer had little impact on survival patterns, except among men ^55 years of age who had a sibling with colon cancer. Stage of the tumour at diagnosis was the major factor associated with survival. There are indications in these data that women are diagnosed when tumours have advanced to a more distant stage. While this may be partly attributed to women having a slighter greater percentage of their tumours in the ascending segment of the colon, 12 this also could be an indication that women have screening sigmoidoscopies less frequently resulting 0.83 ( ) 4 ( ) 6 ( ) 1.12 ( ) 1 ( ) 6 ( ) 1 ( ) ( ) 0.64 ( ) 2.33 ( ) 1.48 ( ) 0.98 ( ) 1.41 ( ) 1.75 ( ) 1.38 ( ) 0.56 ( ) 0.84 ( ) 0.88 ( ) 1.19 ( ) 0.96 ( ) 0.88 ( ) 1.22 ( ) 0.90 ( ) 0.83 ( ) 7 ( ) 2.35 ( ) 1.37 ( ) 1.29 ( ) 1.81 ( ) 1.67 ( ) 1.26 ( ) 0.80 ( ) TABLE 5 Interaction between age at diagnosis, having a sibling with colon cancer, and sex and risk of dying of any cause Age at diagnosis >55 years <55 years Sex Male Female Male Female with colon cancer No Yes No Yes No Yes No Yes 1 06( ) 0.90(0.80-) 8( ) 6( ) 2.50(3-6.10) 0.% ( ) 1.10( )
8 COLON CANCER SURVIVAL 895 TABLE 6 Characteristics of the population by stage at diagnosis Local Regional Stage at diagnosis Distant Unknown N * N % N % N 5, Sex /"-valne Age at diagnosis <5O >65 / -value Site of tumour in the colon* Asceoding Descending < 'Excludes 218 people with unknown site O < CO (30.0) (32.5) (29.9) (33.9) (30.4) (28.1) (35.9) (31.3) (31.3) (30.6) (40.3) (38.4) (27.6) (31.9) (30.5) (30.0) (30.7) (35.1) (35.0) in the tumour being at a more advanced stage at detection. ACKNOWLEDGEMENTS This research was supported by grant CA and contract CN05222 from the National Cancer Institute. We would like to thank Rosemary Dibble of the Utah Cancer Registry and Christi Ramsey for their assistance in the preparation of this manuscript. REFERENCES 1 Ruder A M, Moodie P F, Nelson N A, Choi N W. Does family history of breast cancer improve survival among patients with breast cancer? Am J Obstet Cynecol 1988; 158: (36.9) (39.8) (44.0) (40.1) (37.1) (42.6) (37.8) (38.4) (35.4) (38.6) (34.6) (35.0) (46.5) (37.4) (38.3) (38.0) (39.6) (36.0) (42.2) (22.1) (20.8) (21.6) (21.3) (21.5) (24.5) (21.2) (21.3) (27.1) (21.8) (17.0) (19.2) (15.7) (23.6) (21.7) (22.2) (21.2) (2) (17.2) (1) (7.0) (4.5) (4.7) (1) (4.8) (5 2) (9.0) (6.3) (9.1) (8.2) (7.4) (10.2) (7.1) (9.5) (9.9) (8.5) (7.9) (5.6) 2 Anderson D E, Badzioch M D. Survival in familial breast cancer patients. Cancer 1986; 58: Slattery M L, Berry D T, Kerber R A. Is survival among women diagnosed with breast cancer influenced by family history of cancer? Epidemiology 1993; 4: Lees AW, Jenkins H i. May C L, Cherian G, Lam E W H, Hanson J. Risk factors and 10-year breast cancer survival in northern Alberta. Breast Cancer Res Treat 1989; 13: Albano W A, Recabaren J A, Lynch H T et al. Natural history of hereditary cancer of the breast and colon. Cancer 1982; 50: Kune G A, Kune S, Field B et al. Survival in patients with largebowel cancer. A population-based investigation from the Melbourne Colorectal Cancer Study. Dis Colon Rectum 1990; 33: Lothe R A, Peltomaki P, Meling G I el al. Genomic instability in colorectal cancer relationship to clinicopathological variables and family history. Cancer Res 1993; 53:
9 896 INTERNATIONAL JOURNAL OF EPIDEMIOLOGY 'Skolnick M. The Utah genealogical database: a resource for genetic epidemiology. In: Cflims J, Lyon J L, Skolnick M. Cancer Incidence in Defined Populations. US, Cold Spring Harbor Laboratory, ' Beam L L, Mineau G P, Anderton D L. Fertility Change on the American Frontier. Berkeley: University of California Press, Beahrs O H, Henson D E, Hutter R V P, Myers M H (eds). Manual for Staging of Cancer. Third Edn. Philadelphia: J B Lippincott Company, 1988, Ch. 11. " Kerber R. Statistical methods to calculate risk associated with family history. Genetic Epidemiology 1995 (In press). 12 Slattery M L, Kerber R A. Family history of cancer and colon cancer risk: The Utah Population Database. JNCI 1994; 86: BMDP Statistical Software. Berkeley: University of California Press, Slattery M L, Potter J D, Sorenson A W. Age and risk factors for colon cancer: are there implications for understanding differences in case-control and cohort studies? Cancer Causes Control 1994; 5: Potter J D, McMichael A J. Large bowel cancer in relation to reproductive and hormonal factors: a case-control study. JNCI 1983; 71: Potter J D, Slauery M L, Bostick R M, Gasptur S M. Colon cancer: A review of the epidemiology. Epidemiol Rev 1993; 15: (Revised version received April 1995)
Of the projected nearly 150,000 new cases of large-bowel. A Familial Component to Human Rectal Cancer, Independent of Colon Cancer Risk
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:1080 1084 A Familial Component to Human Rectal Cancer, Independent of Colon Cancer Risk JOHN SCOTT MAUL,* RANDALL W. BURT, and LISA A. CANNON ALBRIGHT *Department
More informationColorectal Cancer Structured Pathology Reporting Proforma DD MM YYYY
Colorectal Cancer Structured Pathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.03). Family name Given name(s) Date of birth DD MM YYYY S1.02 Clinical details
More informationA916: rectum: adenocarcinoma
General facts of colorectal cancer The colon has cecum, ascending, transverse, descending and sigmoid colon sections. Cancer can start in any of the r sections or in the rectum. The wall of each of these
More informationIMAGING GUIDELINES - COLORECTAL CANCER
IMAGING GUIDELINES - COLORECTAL CANCER DIAGNOSIS The majority of colorectal cancers are diagnosed on colonoscopy, with some being diagnosed on Ba enema, ultrasound or CT. STAGING CT chest, abdomen and
More informationColorectal Cancer Demographics and Survival in a London Cancer Network
Cancer Research Journal 2017; 5(2): 14-19 http://www.sciencepublishinggroup.com/j/crj doi: 10.11648/j.crj.20170502.12 ISSN: 2330-8192 (Print); ISSN: 2330-8214 (Online) Colorectal Cancer Demographics and
More informationColon and Rectum. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition
Colon and Rectum Protocol applies to all invasive carcinomas of the colon and rectum. Carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix are excluded. Protocol revision date: January
More informationLOINC. Clinical information. RCPA code. Record if different to report header Operating surgeon name and contact details. Absent.
Complete as narrative or use the structured format below 55752-0 17.02.28593 Clinical information 22027-7 17.02.30001 Record if different to report header Operating surgeon name and contact details 52101004
More informationColorectal Pathway Board (Clinical Subgroup): Imaging Guidelines September 2015
Colorectal Pathway Board (Clinical Subgroup): Imaging Guidelines September 2015 1 Contents Page No. 1. Objective 3 2. Imaging Techniques 3 3. Staging of Colorectal Cancer 5 4. Radiological Reporting 6
More information8. The polyp in the illustration can be described as (circle all that apply) a. Exophytic b. Pedunculated c. Sessile d. Frank
Quiz 1 Overview 1. Beginning with the cecum, which is the correct sequence of colon subsites? a. Cecum, ascending, splenic flexure, transverse, hepatic flexure, descending, sigmoid. b. Cecum, ascending,
More informationBMJ Open. A Nationwide Danish Cohort Study challenging the Categorization into Right Sided and Left Sided Colon Cancer
A Nationwide Danish Cohort Study challenging the Categorization into Right Sided and Left Sided Colon Cancer Journal: BMJ Open Manuscript ID: bmjopen-0-000 Article Type: Research Date Submitted by the
More informationThis is the portion of the intestine which lies between the small intestine and the outlet (Anus).
THE COLON This is the portion of the intestine which lies between the small intestine and the outlet (Anus). 3 4 5 This part is responsible for formation of stool. The large intestine (colon- coloured
More informationSEER EOD AND SUMMARY STAGE ABSTRACTORS TRAINING
SEER EOD AND SUMMARY STAGE ABSTRACTORS TRAINING OVERVIEW What is SEER EOD Ambiguous Terminology General Guidelines EOD Primary Tumor EOD Regional Nodes EOD Mets Site Specific Data Items (SSDI) SEER Summary
More informationRisk of Colorectal Cancer and Adenomas in the Families of Patients With Adenomas
Risk of Colorectal Cancer and Adenomas in the Families of Patients With Adenomas A Population-Based Study in Utah Therèse M.F. Tuohy, PhD 1 ; Kerry G. Rowe, MS 2 ; Geraldine P. Mineau, PhD 1,3 ; Richard
More informationDOES LOCATION MATTER IN COLORECTAL CANCER: LEFT VS RIGHT?
DOES LOCATION MATTER IN COLORECTAL CANCER: LEFT VS RIGHT? By: Dr. Dominik Modest, Medical Department III, Hospital of the University of Munich, Germany Dr. Andrea Sartore-Bianchi, Niguarda Cancer Center,
More informationColon Cancer Prediction based on Artificial Neural Network
Global Journal of Computer Science and Technology Interdisciplinary Volume 13 Issue 3 Version 1.0 Year 2013 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc.
More informationOFCCR CLINICAL DIAGNOSIS AND TREATMENT FORM
OFCCR CLINICAL DIAGNOSIS AND TREATMENT FORM Name: _, OFCCR # _ OCGN # _ OCR Group # _ HIN# Sex: MALE FEMALE UNKNOWN Date of Birth: DD MMM YYYY BASELINE DIAGNOSIS & TREATMENT 1. Place of Diagnosis: Name
More informationFamily History and Risk of Colorectal Cancer in the Multiethnic Population of Hawaii
American Journal of Epidemiology Copyright O 1996 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol 144, No 12 Printed In USA Family History and Risk of Colorectal
More informationUtilization of BRCA Testing. Breast and Ovarian Cancer in Texas
Utilization of BRCA Testing in Older Ode Women with Breast and Ovarian Cancer in Texas Ana M. Rodriguez, MD Assistant Professor Department of Obstetrics and Gynecology University of Texas Medical Branch
More information2012 update. Bowel Cancer. Information for people at increased risk of bowel cancer. Published by the New Zealand Guidelines Group
2012 update Bowel Cancer Information for people at increased risk of bowel cancer Published by the New Zealand Guidelines Group i Contents Introduction 1 The bowel 1 Bowel cancer 3 What are the symptoms
More information[A RESEARCH COORDINATOR S GUIDE]
2013 COLORECTAL SURGERY GROUP Dr. Carl J. Brown Dr. Ahmer A. Karimuddin Dr. P. Terry Phang Dr. Manoj J. Raval Authored by Jennifer Lee A cartoon about colonoscopies. 1 [A RESEARCH COORDINATOR S GUIDE]
More informationA Comparative Study of Rectal and Colonic Carcinoma: Demographic, Pathologic and TNM Staging Analysis
Journal of the Egyptian Nat. Cancer Inst., Vol. 18, 3, September: 2-263, 2006 A Comparative Study of Rectal and ic Carcinoma: Demographic, Pathologic and TNM Staging Analysis TAREK N. EL-BOLKAINY, M.D.;
More informationFROM EDUCATION TO TUMOUR CHARACTERISTICS IN COLORECTAL CANCER: AN ANALYSIS OF THE PATHWAYS
FROM EDUCATION TO TUMOUR CHARACTERISTICS IN COLORECTAL CANCER: AN ANALYSIS OF THE PATHWAYS By Parisa Airia A thesis submitted in conformity with the requirements for the degree of PhD Dalla Lana School
More informationKnow your past, protect your future.
Why do you need a Medical Family Tree? Your medical family tree records your family's health history, and can help you make informed decisions for health. In the course of creating your medical family
More informationFACT SHEET 49. What is meant by a family history of bowel cancer? What is bowel cancer? What causes bowel cancer?
Important points The most important factors that can influence an individual s chance of developing bowel cancer are getting older and having a family history of bowel cancer A family history of bowel
More informationGastric Cancer Histopathology Reporting Proforma
Gastric Cancer Histopathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.01). S1.01 Identification Family name Given name(s) Date of birth Sex Male Female Intersex/indeterminate
More informationQ: In order to use the code 8461/3 (serous surface papillary) for ovary, does it have to say the term "surface" on the path report?
Q&A Session for Collecting Cancer Data: Ovary Q: In order to use the code 8461/3 (serous surface papillary) for ovary, does it have to say the term "surface" on the path report? A: We reviewed both the
More informationAdvice about familial aspects of breast cancer and epithelial ovarian cancer
Advice about familial aspects of breast cancer and epithelial ovarian cancer a guide for health professionals FEBRUARY 2006 These guidelines contain three parts: 1. Information for health professionals
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators
More informationCOLORECTAL CANCER FAISALGHANISIDDIQUI MBBS; FCPS; PGDIP-BIOETHICS; MCPS-HPE
COLORECTAL CANCER FAISALGHANISIDDIQUI MBBS; FCPS; PGDIP-BIOETHICS; MCPS-HPE PROFESSOR OF SURGERY & DIRECTOR, PROFESSIONAL DEVELOPMENT CENTRE J I N N A H S I N D H M E D I C A L U N I V E R S I T Y faisal.siddiqui@jsmu.edu.pk
More informationHeather Hampel, MS, CGC Professor, Division of Human Genetics
Familial, Hereditary, and Early Age Onset Colorectal Cancer: A Module Designed to Assist Primary Care Clinician s in the Identification of Individuals at Increased Risk and Facilitate Earliest Possible
More informationChapter 13 Cancer of the Female Breast
Lynn A. Gloeckler Ries and Milton P. Eisner INTRODUCTION This study presents survival analyses for female breast cancer based on 302,763 adult cases from the Surveillance, Epidemiology, and End Results
More informationAlison Douglass Gillian Lieberman, MD. November. Colon Cancer. Alison Douglass, Harvard Medical School Year III Gillian Lieberman, MD
November Colon Cancer Alison Douglass, Harvard Medical School Year III Our Patient Mr. K. is a 67 year old man with no prior medical problems other than hemorrhoids which have caused occasional rectal
More information11/21/13 CEA: 1.7 WNL
Case Scenario 1 A 70 year-old white male presented to his primary care physician with a recent history of rectal bleeding. He was referred for imaging and a colonoscopy and was found to have adenocarcinoma.
More informationUnderstanding Your Genetic Test Result. Positive for a Deleterious Mutation or Suspected Deleterious
Understanding Your Genetic Test Result Positive for a Deleterious Mutation or Suspected Deleterious This workbook is designed to help you understand the results of your genetic test and is best reviewed
More informationCollaborative Stage for TNM 7 - Revised 06/30/2008 [ Schema ]
Collaborative Stage for TNM 7 - Revised 06/30/2008 [ Schema ] CS Tumor Size 000 No mass/tumor found 001-988 001-988 millimeters (code exact size in millimeters) 989 989 millimeters or larger 990 Microscopic
More informationReproductive factors related to the risk of colorectal cancer by subsite: a case-control analysis
British Journal of Cancer (1999) 79(11/12), 1901 1906 1999 Cancer Research Campaign Article no. bjoc.1998.0302 Reproductive factors related to the risk of colorectal cancer by subsite: a case-control analysis
More informationPreoperative Data Colorectal Cancer Database
Preoperative Data Please place patient label here Patient Information Patient s Last Name First Middle Initial UR MH MP Birth Date Sex Post Code / / M F ECOG (see codes below) Date of Diagnosis Consultant
More informationSurgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database
Surgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database Hadi Khan, MD 1, Adam J. Olszewski, MD 2 and Ponnandai S. Somasundar, MD 1 1 Department
More informationProactive Patient Paves the Way for Genetic Testing of Eight Family Members
CASE STUDY Proactive Patient Paves the Way for Genetic Testing of Eight Family Members Quick Summary Samar Mohite * was diagnosed with colon adenocarcinoma at the age of 49 years. Genetic counselling was
More informationInformation for You and Your Family
Information for You and Your Family What is Prevention? Cancer prevention is action taken to lower the chance of getting cancer. In 2017, more than 1.6 million people will be diagnosed with cancer in the
More informationColorectal adenocarcinoma leading cancer in developed countries In US, annual deaths due to colorectal adenocarcinoma 57,000.
Colonic Neoplasia Remotti Colorectal adenocarcinoma leading cancer in developed countries In US, annual incidence of colorectal adenocarcinoma 150,000. In US, annual deaths due to colorectal adenocarcinoma
More informationTable S2 Study group sample sizes for CEA, CYFRA21-1 and CA125 determinations.
Supplementary Data Table S Clinico-pathological data associated with malignant and benign cases Primary site Early stage Late stage Caecum 3 (5%) 4 (20%) (5%) Ascending colon 6 (30%) 2 (0%) 0 (0%) Transverse
More informationCancer Risk Assessment Questionnaire
Information about your health, lifestyle, and family history will help us determine your risk for cancer. If you already have cancer, it can help us determine the chance your cancer was caused by an inherited
More informationNATIONAL BOWEL CANCER AUDIT The feasibility of reporting Patient Reported Outcome Measures as part of a national colorectal cancer audit
NATIONAL BOWEL CANCER AUDIT The feasibility of reporting Patient Reported Outcome Measures as part of a national colorectal cancer audit NBOCA: Feasibility Study Date of publication: Thursday 9 th August
More informationNeoplastic Colon Polyps. Joyce Au SUNY Downstate Grand Rounds, October 18, 2012
Neoplastic Colon Polyps Joyce Au SUNY Downstate Grand Rounds, October 18, 2012 CASE 55M with Hepatitis C, COPD (FEV1=45%), s/p vasectomy, knee surgery Meds: albuterol, flunisolide, mometasone, tiotropium
More informationStaging Challenges in Lower GI Cancers. Disclosure of Relevant Financial Relationships. AJCC 8 th edition and CAP protocol updates
Staging Challenges in Lower GI Cancers Sanjay Kakar, MD University of California, San Francisco March 05, 2017 Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education
More informationStage III Colon Cancer Susquehanna Cancer Center Warren L Robinson, MD, FACP May 9, 2007
Stage III Colon Cancer Susquehanna Cancer Center 1997-21 Warren L Robinson, MD, FACP May 9, 27 Stage III Colon Cancer Susquehanna Cancer Center 1997-21 Colorectal cancer is the third most common cancer
More informationCancer survival in Hong Kong SAR, China,
Chapter 5 Cancer survival in Hong Kong SAR, China, 1996 2001 Law SC and Mang OW Abstract The Hong Kong cancer registry was established in 1963, and cancer registration is done by passive and active methods.
More informationIncreased Melanoma Risk in Individuals With Papillary Thyroid Carcinoma
Research Original Investigation Increased Melanoma Risk in Individuals With Papillary Thyroid Carcinoma Gretchen M. Oakley, MD; Karen Curtin, PhD; Lester Layfield, MD; Elke Jarboe, MD; Luke O. Buchmann,
More informationSeventh Edition Staging 2017 Colorectum. Overview. This webinar is sponsored by. the Centers for Disease Control and Prevention.
Seventh Edition Staging 2017 Colorectum Donna M. Gress, RHIT, CTR Validating science. Improving patient care. No materials in this presentation may be repurposed in print or online without the express
More informationCancer in the Northern Territory :
Cancer in the Northern Territory 1991 21: Incidence, mortality and survival Xiaohua Zhang John Condon Karen Dempsey Lindy Garling Acknowledgements The authors are grateful to the many people, who have
More informationPlease read the following instructions carefully
Grand River Regional Cancer Centre 835 King Street West, PO Box 9056 Kitchener, ON N2G 1G3 Tel: (519) 749-4370 x2832 Fax: (519) 749-4394 Dear: You have been referred to the High Risk Ontario Breast Screening
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationGastric and Colon Cancer. Dr. Andres Wiernik 2017
Gastric and Colon Cancer Dr. Andres Wiernik 2017 GASTRIC CANCER Gastric Cancer Classification Epidemiology General principles of Management 25% GE Junction Gastric Cancer 75% Gastric Cancer Epidemiology
More informationPROCARE FINAL FEEDBACK
1 PROCARE FINAL FEEDBACK General report 2006-2014 Version 2.1 08/12/2015 PROCARE indicators 2006-2014... 3 Demographic Data... 3 Diagnosis and staging... 4 Time to first treatment... 6 Neoadjuvant treatment...
More informationLynch Syndrome (HNPCC) and MYH-Associated Polyposis (MAP)
Lynch Syndrome (HNPCC) and MYH-Associated Polyposis (MAP) A Patient s Guide to risk assessment Hereditary Cancer Testing: Is it Right for You? This workbook is designed to help you decide if hereditary
More informationRectal Cancer Cookbook Update. A. JOURET-MOURIN with the collaboration of A Hoorens,P Demetter, G De Hertogh,C Cuvelier and C Sempoux
Rectal Cancer Cookbook Update A. JOURET-MOURIN with the collaboration of A Hoorens,P Demetter, G De Hertogh,C Cuvelier and C Sempoux Prof Dr A Jouret-Mourin, Department of Pathology, UCL, St Luc, Brussels
More informationUnderstanding Your Genetic Test Result. Positive for a Deleterious Mutation or Suspected Deleterious
Understanding Your Genetic Test Result Positive for a Deleterious Mutation or Suspected Deleterious This workbook is designed to help you understand the results of your genetic test and is best reviewed
More informationPhysical Activity and Colorectal Cancer
American Journal of Epidemiology Copyright 2003 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 158, No. 3 Printed in U.S.A. DOI: 10.1093/aje/kwg134 Physical Activity and
More informationLynch Syndrome (HNPCC) and MYH-Associated Polyposis (MAP)
Lynch Syndrome (HNPCC) and MYH-Associated Polyposis (MAP) A Patient s Guide to risk assessment Hereditary Cancer Testing: Is it Right for You? This workbook is designed to help you decide if hereditary
More informationAJCC 7 th Edition Staging Disease Site Webinar Colorectum
AJCC 7 th Edition Staging Disease Site Webinar Colorectum Donna M. Gress, RHIT, CTR Validating science. Improving patient care. This presentation was supported by the Cooperative Agreement Number DP13-1310
More information7 th Edition Staging. AJCC 7 th Edition Staging. Disease Site Webinar. Colorectum. Overview. This webinar is sponsored by
AJCC 7 th Edition Staging Colorectum Donna M. Gress, RHIT, CTR Validating science. Improving patient care. This presentation was supported by the Cooperative Agreement Number DP13-1310 from The Centers
More informationadverse effect on survival after operation for colorectal cancer
Annals of the Royal College of Surgeons of England (1993) vol. 75, 261-267 Blood transfusion does not have an adverse effect on survival after operation for colorectal cancer A Sene MA FRCS Senior Surgical
More informationReport on Cancer Statistics in Alberta. Kidney Cancer
Report on Cancer Statistics in Alberta Kidney Cancer November 29 Surveillance - Cancer Bureau Health Promotion, Disease and Injury Prevention Report on Cancer Statistics in Alberta - 2 Purpose of the Report
More informationFor identification, support and follow up related to Familial Gastrointestinal Cancer conditions. South Island Cancer Nurses Network September 2013
For identification, support and follow up related to Familial Gastrointestinal Cancer conditions South Island Cancer Nurses Network September 2013 Who are we? Specialist multidisciplinary team: Nurse coordinators,
More informationAdenomatous Polyposis Syndromes (FAP/AFAP and MAP)
A Patient s Guide to risk assessment Adenomatous Polyposis Syndromes (FAP/AFAP and MAP) Hereditary Cancer Testing: Is it Right for You? This workbook is designed to help you decide if hereditary cancer
More informationRisk of Colorectal Cancer (CRC) Hereditary Syndromes in GI Cancer GENETIC MALPRACTICE
Identifying the Patient at Risk for an Inherited Syndrome Sapna Syngal, MD, MPH, FACG Director, Gastroenterology Director, Familial GI Program Dana-Farber/Brigham and Women s Cancer Center Associate Professor
More informationAn Overview of Survival Statistics in SEER*Stat
An Overview of Survival Statistics in SEER*Stat National Cancer Institute SEER Program SEER s mission is to provide information on cancer statistics in an effort to reduce the burden of cancer among the
More information12: BOWEL CANCER IN FAMILIES
12: BOWEL CANCER IN FAMILIES 12.1 INTRODUCTION TO GENETICS AND INHERITANCE The human body is made up of billions of cells (such as skin cells, brain cells, nerve cells, etc). Almost every cell in the body
More informationLifestyle and Colon Cancer: An Assessment of Factors Associated with Risk
American Journal of Epidemiology Copyright 1999 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 150, No. 8 Printed In U.SJ\. Lifestyle and Colon Cancer: An
More informationThe Rodger C. Haggitt Memorial Lecture
The Rodger C. Haggitt Memorial Lecture I got an email on 4/22/14 from Hala El Zamaity inviting me to give this lecture and giving me this topic: The ever changing TNM classification and its implication
More informationReport on Cancer Statistics in Alberta. Melanoma of the Skin
Report on Cancer Statistics in Alberta Melanoma of the Skin November 29 Surveillance - Cancer Bureau Health Promotion, Disease and Injury Prevention Report on Cancer Statistics in Alberta - 2 Purpose of
More informationGastric (Stomach) Cancer
Gastric (Stomach) Cancer Gastric cancer is a disease in which malignant (cancer) cells form in the lining of the stomach. The stomach is a J-shaped organ in the upper abdomen. It is part of the digestive
More informationAdenomatous Polyposis Syndromes (FAP/AFAP and MAP)
A Patient s Guide to risk assessment Adenomatous Polyposis Syndromes (FAP/AFAP and MAP) Hereditary Cancer Testing: Is it Right for You? This workbook is designed to help you decide if hereditary cancer
More informationChapter 5: Epidemiology of MBC Challenges with Population-Based Statistics
Chapter 5: Epidemiology of MBC Challenges with Population-Based Statistics Musa Mayer 1 1 AdvancedBC.org, Abstract To advocate most effectively for a population of patients, they must be accurately described
More informationCase presentation. Eran Zittan. MD Mount Sinai Hospital, Toronto, Canada. Emek Medical Center, Afula, Israel. March, 2016
Case presentation Eran Zittan. MD Mount Sinai Hospital, Toronto, Canada. Emek Medical Center, Afula, Israel. March, 2016 60 y/o man with long standing UC+PSC. Last 10 years on clinical and endoscopic remission.
More informationColon Cancer , The Patient Education Institute, Inc. oc Last reviewed: 05/17/2017 1
Colon Cancer Introduction Colon cancer is fairly common. About 1 in 15 people develop colon cancer. Colon cancer can be a life threatening condition that affects the large intestine. However, if it is
More information2014/2015 FCDS Educational Webcast Series
2014/2015 FCDS Educational Webcast Series February 19, 2015 Steven Peace, CTR 2015 Update; Background, Anatomy, Risk Factors, Screening Guidelines, MPH Rules Review AJCC TNM 7 th ed, SS2000, CSv02.05 and
More informationAcute: Symptoms that start and worsen quickly but do not last over a long period of time.
Cancer Glossary Acute: Symptoms that start and worsen quickly but do not last over a long period of time. Adjuvant therapy: Treatment given after the main treatment. It usually refers to chemotherapy,
More informationCommon Questions about Cancer
6 What is cancer? Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells. The cancer cells form tumors that destroy normal tissue. If cancer cells break away from
More informationThe benefit of. knowing. Genetic testing for hereditary cancer. A patient support guide
The benefit of knowing Genetic testing for hereditary cancer A patient support guide Does cancer run in your family? Cancer is more common in some families. Sometimes cancer is caused by a change in a
More informationCancer in Halton. Halton Region Cancer Incidence and Mortality Report
Cancer in Halton Halton Region Cancer Incidence and Mortality Report 2008 2012 The Regional Municipality of Halton March 2017 Reference: Halton Region Health Department, Cancer in Halton: Halton Region
More informationGrand Rounds. Des Moines University. May 5, Durado Brooks, MD, MPH Director, Cancer Control Intervention American Cancer Society
Grand Rounds Des Moines University May 5, 2016 Durado Brooks, MD, MPH Director, Cancer Control Intervention American Cancer Society Case Summary Mrs. J is a 56 y o w female complaining of always tired;
More informationOverview. Collecting Cancer Data: Colon 11/5/2009. Collecting Cancer Data: NAACCR Webinar Series 1. Agenda NAACCR WEBINAR SERIES
Collecting Cancer Data: Colon 11/5/2009 Collecting Cancer Data: Colon/Rectum/Appendix NAACCR 2009 2010 WEBINAR SERIES Agenda Overview Treatment MP/H Rules CSv2 2 Overview Colon/Rectum/Appendix 2009 2010
More informationNeoplasms of the Colon and of the Rectum
Neoplasms of the Colon and of the Rectum 2 0 1 5-2 0 1 6 F C D S E D U C A T I O N A L W E B C A S T S E R I E S S T E V E N P E A C E, B S, C T R F E B R U A R Y 1 8, 2 0 1 6 2016 Focus o Anatomy o SS
More informationA Patient s Guide to. Hereditary Ovarian Cancer: Is Hereditary Cancer Testing Right for You?
A Patient s Guide to Hereditary Ovarian Cancer: Is Hereditary Cancer Testing Right for You? What is Hereditary Cancer? Most cancers occur in people who do not have a strong family history of that cancer.
More informationReport on Cancer Statistics in Alberta. Breast Cancer
Report on Cancer Statistics in Alberta Breast Cancer November 2009 Surveillance - Cancer Bureau Health Promotion, Disease and Injury Prevention Report on Cancer Statistics in Alberta - 2 Purpose of the
More informationImaging in gastric cancer
Imaging in gastric cancer Gastric cancer remains a deadly disease because of late diagnosis. Adenocarcinoma represents 90% of malignant tumors. Diagnosis is based on endoscopic examination with biopsies.
More informationNasogastric tube. Stomach. Pylorus. Duodenum 1. Duodenum 2. Duodenum 3. Duodenum 4
Esophagus Barium Swallow Stomach and Duodenum 4 year old Upper GI Nasogastric tube Stomach and Duodenum 4 year old Upper GI Nasogastric tube Stomach Pylorus Duodenum 1 Duodenum 2 Duodenum 3 Duodenum 4
More informationClinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients
Yonago Acta medica 2012;55:57 61 Clinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients Hiroaki Saito, Seigo Takaya, Yoji Fukumoto, Tomohiro Osaki, Shigeru Tatebe and Masahide
More informationUnderstanding Your Genetic Test Result. Positive for Two Copies of an MYH Mutation
Understanding Your Genetic Test Result Positive for Two Copies of an MYH Mutation This workbook is designed to help you understand the results of your genetic test and is best reviewed with your healthcare
More informationColorectal Cancer: Preventable, Beatable, Treatable. American Cancer Society
Colorectal Cancer: Preventable, Beatable, Treatable American Cancer Society Reviewed/Revised May 2018 What we ll be talking about How common is colorectal cancer? What is colorectal cancer? What causes
More informationCANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I
CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I Changes and Clarifications 16 th Edition April 15, 2016 Quick Look- Updates to Volume
More informationEthnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer. Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD,
Ethnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD, MD, Paul Hebert, PhD, Michael C. Iannuzzi, MD, and
More informationGenetic Risk Evaluation and Testing Program
INSTRUCTIONS: Please complete this form to the best of your ability PRIOR to your appointment. Please remember to list ALL relatives, both living and deceased, regardless of if they have had cancer or
More informationProstate cancer was the most commonly diagnosed type of cancer among Peel and Ontario male seniors in 2002.
Cancer HIGHLIGHTS Prostate, colorectal, and lung cancers accounted for almost half of all newly diagnosed cancers among Peel seniors in 22. The incidence rates of lung cancer in Ontario and Peel have decreased
More informationMr Chris Wakeman. General Surgeon University of Otago, Christchurch. 12:15-12:40 Management of Colorectal Cancer
Mr Chris Wakeman General Surgeon University of Otago, Christchurch 12:15-12:40 Management of Colorectal Cancer Bowel cancer Chris Wakeman Colorectal Surgeon Christchurch Sam Simon (Simpsons) Elizabeth
More informationCELLULAR PATHOLOGY TURNAROUND TIMES
Title: - Summary CELLULAR PATHOLOGY TURNAROUND TIMES These are average figures for some key specimens in days for the month of November 2016. The times include weekends when the laboratory is closed. The
More information